» Articles » PMID: 28126403

Binding of Amphipathic Cell Penetrating Peptide P28 to Wild Type and Mutated P53 As Studied by Raman, Atomic Force and Surface Plasmon Resonance Spectroscopies

Overview
Publisher Elsevier
Specialties Biochemistry
Biophysics
Date 2017 Jan 28
PMID 28126403
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mutations within the DNA binding domain (DBD) of the tumor suppressor p53 are found in >50% of human cancers and may significantly modify p53 secondary structure impairing its function. p28, an amphipathic cell-penetrating peptide, binds to the DBD through hydrophobic interaction and induces a posttranslational increase in wildtype and mutant p53 restoring functionality. We use mutation analyses to explore which elements of secondary structure may be critical to p28 binding.

Methods: Molecular modeling, Raman spectroscopy, Atomic Force Spectroscopy (AFS) and Surface Plasmon Resonance (SPR) were used to identify which secondary structure of site-directed and naturally occurring mutant DBDs are potentially altered by discrete changes in hydrophobicity and the molecular interaction with p28.

Results: We show that specific point mutations that alter hydrophobicity within non-mutable and mutable regions of the p53 DBD alter specific secondary structures. The affinity of p28 was positively correlated with the β-sheet content of a mutant DBD, and reduced by an increase in unstructured or random coil that resulted from a loss in hydrophobicity and redistribution of surface charge.

Conclusions: These results help refine our knowledge of how mutations within p53-DBD alter secondary structure and provide insight on how potential structural alterations in p28 or similar molecules improve their ability to restore p53 function.

General Significance: Raman spectroscopy, AFS, SPR and computational modeling are useful approaches to characterize how mutations within the p53DBD potentially affect secondary structure and identify those structural elements prone to influence the binding affinity of agents designed to increase the functionality of p53.

Citing Articles

Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.

Nhan N, Yamada T, Yamada K Int J Mol Sci. 2023; 24(16).

PMID: 37629112 PMC: 10454368. DOI: 10.3390/ijms241612931.


The brain-penetrant cell-cycle inhibitor p28 sensitizes brain metastases to DNA-damaging agents.

Mander S, Gorman G, Coward L, Christov K, Green A, Das Gupta T Neurooncol Adv. 2023; 5(1):vdad042.

PMID: 37197737 PMC: 10184511. DOI: 10.1093/noajnl/vdad042.


Targeting p53 pathways: mechanisms, structures, and advances in therapy.

Wang H, Guo M, Wei H, Chen Y Signal Transduct Target Ther. 2023; 8(1):92.

PMID: 36859359 PMC: 9977964. DOI: 10.1038/s41392-023-01347-1.


Cell-Penetrating Peptides (CPPs) as Therapeutic and Diagnostic Agents for Cancer.

Bottens R, Yamada T Cancers (Basel). 2022; 14(22).

PMID: 36428639 PMC: 9688740. DOI: 10.3390/cancers14225546.


When is an obscurin variant pathogenic? The impact of Arg4344Gln and Arg4444Trp variants on protein-protein interactions and protein stability.

Fukuzawa A, Koch D, Grover S, Rees M, Gautel M Hum Mol Genet. 2021; 30(12):1131-1141.

PMID: 33438037 PMC: 8188405. DOI: 10.1093/hmg/ddab010.